Located in Fort Myers, Florida, Lee Health is the largest healthcare system in Southwest Florida consisting of four acute care and two specialty hospitals and over 1,400 beds.
“This data demonstrates that innovation at Lee Health is leading to improved care for our patients and also reducing costs,” said John Armistead, Lee Health System Director Pharmacy. “The testing is helping to get our patients suspected of sepsis on the right therapy faster.” 2
Faster Targeted Therapy: T2Candida enabled patients to receive targeted therapy 28 hours faster. Patients suspected of a Candida infection that were tested on the T2Dx received targeted therapy nearly 6 times faster, in only 6 hours compared to conventional practices that took 34 hours.
Improved stewardship and pharmacy savings: The major findings in this study are the decreased time to initiation of targeted antifungal therapy when a T2Candida-directed treatment strategy was employed versus that of a BC-directed therapy approach and the avoidance of empiric therapy in 58.4% (101/173) of T2Candida-negative patients.2
The decreased utilization of empirical micafungin therapy observed in Phase 2 would result in a total savings of $280 per tested patient in antifungal costs alone when compared with historical control data from Phase 1.2
Faster Results: In a separate study the T2Bacteria Panel allowed testing from whole blood samples and provided final results within 4 hours. T2Bacteria Panel provided positive and negative results approximately 20 hours and 122 hours sooner than blood cultures, respectively (p<0.001). T2Bacteria Panel identified all organisms identified by blood cultures of the bacteria included on the panel.3
Stewardship Tool: In the same study a total of 36 opportunities for de-escalation were identified, such a potential to de-escalate coverage for S. aureus and/or P. aeruginosa. The high negative predictive value of the T2Bacteria Panel suggests utility in guiding early antibiotic de-escalation of coverage for organisms not identified.3